PiPCast™ | Expedited Patent Prosecution in Australia and New Zealand
PiPCast™ | Expedited Patent Prosecution in Australia and New Zealand
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Kate Legge
Kate is an experienced IP and patent lawyer, providing IP leadership for pharmaceutical product development and commercialisation in global markets – from initial scoping through to post-launch. She has developed and implemented global IP strategies over more than 15 years at multi-national pharmaceutical companies. She is an Australian qualified and registered legal practitioner, and has a Master’s degree in IP Law and a BSc in biochemistry.
See Kate's full profile
Jayne Jagot appointed to Australia’s High Court bench – a new era for diversity and for patent law
The Australian High Court will have an experienced intellectual property judge on its bench, with the appointment of...
PiPCast™ | Biosimilars – strategies for AU market entry
In this PiPCast®, Naomi Pearce and Kate Legge walk through the key IP strategies biosimilars companies are using to enable market entry globally, and canvas biosimilar litigation in Australian courts. They also discuss recent litigation settlement activity and lessons learnt.
PiPCast™ | The implications of recent DABUS Federal Court decisions for life sciences companies
In this PiPCast™, Kate Legge and Grant Shoebridge discuss whether a patent inventor must be human or can include artificial intelligence systems in Australia, and look to the future legal developments in this space.
High Court has a bet each way on electronic gaming machine patent
Even the High Court of Australia could not come to a majority decision on the thorny question of the patentability of...
Full Court dismisses Boehringer appeal on obviousness of veterinary injectable formulation
The Full Court’s decision in Boehringer Ingelheim Animal Health USA Inc., v Intervet International B.V. [2022] FCAFC...
WTO Members endorse latest COVID IP waiver draft
The key terms of an updated draft covid IP waiver have been released by the WTO. The draft includes terms intended to...
Medicinal Cannabis in Australia | Part 5: Making therapeutic claims: advertising and labelling of medicinal cannabis products
Introduction The promotion of medicinal cannabis products presents some specific challenges given that very few such...
Medicinal Cannabis in Australia | Part 2: Patient access via the Special Access Scheme (SAS) and Authorised Prescriber (AP) pathways
Introduction As noted in part 1 of our blog series, the vast majority of medicinal cannabis products are not...
Pharmacia’s Dynastat patent expires before injunction ordered; but validity challenge means section 19 certification is still issued
We recently reported on the decision in Pharmacia LLC v Juno Pharmaceuticals Pty Ltd [2022] FCA 92 in which the...
The Full Federal Court overturns AI inventorship in Australia
An enlarged bench of the Full Court of the Federal Court has overturned a first instance decision, reported here, by...
Patent litigation in Australia just got a little cheaper
Full Court confirms duplicative expert evidence legitimately excluded on discretionary grounds
The Full Court’s refusal of leave to appeal today in Novartis AG v Pharmacor Pty Limited [2022] FCAFC 58 is good news...
Pharmacia’s Dynastat patent valid, imminent patent expiry no reason to avoid injunction
Introduction Pharmacia LLC and Pfizer Australia Pty Ltd (together, Pharmacia) have partially succeeded at first...
PTE alert: Patent Office cancellation of PTE paves the way for potential launch of generic YASMIN products
We have previously reported on a number of Federal Court decisions in 2021 invalidating patent term extensions (PTEs)...
Comments period on draft new National Medicines Policy extended – now closing on 2 March
Last week we alerted you to the release of a draft new National Medicines Policy (NMP) for public comment. The draft...
No time to lose! Comments on the consultation draft of the new National Medicines Policy close on 16 February
On 2 February a draft of a new National Medicines Policy (NMP) was made available for public comment. The draft NMP...